MMF induction is a viable alternative to cyclophosphamide for treating mixed proliferative lupus nephritis in children. Oral mycophenolate mofetil (MMF) is as effective as intravenous cyclophosphamide ...

In children with lupus nephritis, neurological manifestations at the time of kidney biopsy, age, and eGFR predicted greater risk of CKD progression. Investigators have identified predictors of chronic ...

Detailed price information for Aurinia Pharm Ord (AUPH-Q) from The Globe and Mail including charting and trades.

With this approval, pediatric patients aged five years and older with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration. GSK plc (LSE/NYSE: GSK) today ...

Benlysta is a human monoclonal antibody that was approved for the treatment of lupus in adults by the U.S. Food and Drug Administration (FDA) in 2011 and for lupus nephritis in adults in 2020.

Investing.com -- The U.S. Food and Drug Administration (FDA) has approved Roche Holding AG’s (SIX:RO) Gazyva/Gazyvaro (obinutuzumab) for treating adult patients with active lupus nephritis who are ...

Lupus nephritis is a serious complication of lupus that is caused by inflammation of the kidneys. It affects up to 60% of people with lupus and usually occurs within 5 years of diagnosis. If left ...

Positive Phase III Results For Roche's Gazyva/Gazyvaro In Children And Young Adults With Idiopathic Nephrotic Syndrome. <li /> Gazyva/Gazyvaro versus mycophenolate mofetil shows significantly more ...

FDA approval based on superiority of Gazyva/Gazyvaro over standard therapy alone, as shown in phase II NOBILITY and phase III REGENCY data1,2Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody ...